For example, inhibition of interleukin 6 (IL-6) was found to facilitate therapeutic activity when the anti-IL-6 antibody siltuximab was taken in clinical trials of patients with platinum-resistant ovarian cancer [39]. Here, IL6 is linked to ovarian carcinoma.